MELANOMA

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This study looks at whether giving immunotherapy infusions in the morning improves outcomes for people with advanced melanoma. Researchers will compare morning versus afternoon/evening dosing in 108 participants. The goal is to see if aligning treatment with the body's natural im…

This early-phase trial tests a virus called DNX-2401, designed to infect and destroy melanoma cells in the brain and body. About 50 adults with stage IV melanoma will receive injections to find the safest dose and number of treatments. The main goal is to check for side effects, …

This Phase 1 trial tests whether HLX18, a biosimilar of the cancer drug OPDIVO, works similarly in people with esophageal, melanoma, or bladder cancer after their tumors have been surgically removed. About 174 participants will receive either HLX18 or OPDIVO to compare how the dr…

This phase II trial tests two drugs—SHR-1701 (an immunotherapy) and famitinib (which cuts off tumor blood supply)—given before surgery for resectable mucosal melanoma, a rare and aggressive skin cancer. After surgery, treatment is tailored based on how well the tumor responded. T…

This phase 2 trial tests three immune-boosting drugs (cemiplimab, fianlimab, and ipilimumab) given before surgery in 20 people with advanced but removable melanoma. The goal is to see if the combination is safe and can shrink tumors, potentially improving outcomes. Participants m…

This study tests whether a new drug called Bmab1700 works the same as the approved immunotherapy Opdivo in people with melanoma who have had their tumors surgically removed. The trial will involve 120 adults with stage IIB to IV melanoma. Researchers will compare how the drugs mo…

This trial tests AVT32-DRL_PB, a biosimilar (copy) of the cancer drug Keytruda, in 120 people with stage IIB/C or III melanoma whose tumors were fully removed. Half get the biosimilar, half get Keytruda, every 3 weeks. The main goal is to see if drug levels in the blood are simil…

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…

This pilot trial tests whether adding emotional support to a cancer information website helps young adults (ages 20-39) with thyroid, melanoma, or testicular cancer feel less worried and distressed. 142 participants will either get general cancer info or the same info plus person…

This study tests whether having melanoma patients regularly report their symptoms through an electronic tool, combined with quick access to specialist care, can improve the management of side effects from immune checkpoint inhibitors. These drugs can cause immune-related side eff…

This early-phase study tests whether adding malic acid (a natural fruit acid) to standard immunotherapy is safe for people with solid tumors like colorectal, lung, or melanoma cancer. About 30 participants will take malic acid by mouth while continuing their immunotherapy. The ma…

This study screens up to 1,000 people with personal or family histories of certain cancers to see if they qualify for ongoing genetics research at the National Cancer Institute. Participants fill out a 15-20 minute online survey about their health and family history. No treatment…

This study tests whether an online training platform called DermLoop Learn can improve how pathologists diagnose melanoma from skin lesion images. 258 pathologists will be randomly assigned to receive the training or not, and their diagnostic accuracy will be compared against a p…

This study will test whether immunotherapy drugs (immune checkpoint inhibitors) change how the liver processes other medications. About 80 adults with various cancers who are starting immunotherapy will take a low-dose cocktail of 7 common drugs. Researchers will measure drug lev…

This study looks at whether eating more fiber helps melanoma patients respond better to immunotherapy. Researchers will track the fiber intake of 60 patients using a special questionnaire and see if those who eat more fiber have less cancer recurrence or progression. The goal is …

This study will follow 600 people with early-stage solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy before surgery. Researchers will collect blood and tumor samples at several time points to see how the immune system responds. …